Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

ABSTRACT: We report RNAseq gene expression data following ARS-1620 treatment and shKRAS expressing cells (NCI-H358). We also compare gene expression changes following treatment with ARS-1620 or trametinib in NCI-H358, LU65 (KRAS-G12C+), and A549 (KRAS-G12S+) cells. Additionally we report a time course (4, 24, 48hr) of ARS-1620 and trametinib treated NCI-H358 cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103021 | GEO | 2018/01/24

REPOSITORIES: GEO